Operator

Good day, and thank you for standing by. Welcome to the Almirall's First Quarter 202 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Pablo Divasson, Head of Investor Relations. Please go ahead.

Pablo Divasson Fraile
Senior Director of Investor Relations

Thank you very much, Matalena. Good morning, everyone. Thank you for joining us for today's quarterly earnings update and review of Almirall's first quarter financial results for 2026. As always, we are sharing the slides we are using today in the Investors section of almirall.com.

Please move to Slide #2. Let me remind you that information presented in this call contains forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause actual results to materially differ from what we are sharing today.

Please move to Slide 3. Presenting today, we have Carlos Gallardo, Chairman and Chief Executive Officer; Jon Garay, Chief Financial Officer; and Karl Ziegelbauer, Chief Scientific Officer. Carlos will start with the business highlights of the first quarter, followed by an update on biologics as the key growth drivers of our medical dermatology portfolio. Karl will provide you with an update on the